immunological signatures to predict outcomes in patients with tnbc
Published 2 years ago • 258 plays • Length 1:22Download video MP4
Download video MP3
Similar videos
-
1:03
new directions in immunotherapy for improving outcomes in tnbc
-
1:26
the association of the her2dx signatures with survival in tnbc
-
1:14
the importance of a biomarker-directed approach in triple-negative breast cancer
-
2:58
imprint immune signature in 10,000 early-stage breast cancer from the real-world flex database
-
1:02
challenges in identifying predictive markers to icis in triple-negative breast cancer
-
2:28
improving breast cancer treatment: incorporating immune predictors for better outcomes
-
1:27
what to do in patients with early-stage tnbc who have not achieved a pcr?
-
2:05
treatment advances in tnbc
-
2:55
systemic immune response to durvalumab concomitant with neoadjuvant chemotherapy in early stage tncb
-
7:26
i-spy 2: immunotherapy biomarkers in early breast cancer
-
8:01
immune oncology in breast cancer: keynote-086, nci 10013, & aipac
-
4:20
keynote-522: 5-year follow-up of pembrolizumab in triple-negative breast cancer
-
57:18
translating progress with immunotherapies and targeted agents into improved outcomes in tnbc
-
1:34
strategies to improve the response to immunotherapy in tnbc
-
1:29
lig1 deletion predicts chemotherapy resistance in triple-negative breast cancer
-
5:20
estimating outcomes in triple negative breast cancer
-
31:24
harnessing the immune system in the treatment of triple-negative breast cancer
-
2:25
new technology allows important discovery in triple negative breast cancer
-
2:23
prognosis and trends in chemotherapy use for patients with stage ia tnbc